HealthBeacon PLC HealthBeacon - HBCN - Notice of Annual General Meeting

Healthbeacon

04/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230804:nRSD2894Ia&default-theme=true

RNS Number : 2894I  HealthBeacon PLC  04 August 2023

4 August 2023

HealthBeacon plc

 

Notice of Annual General Meeting

 

Dublin, HealthBeacon plc ("HealthBeacon" or "the Company"), today announces
that the Letter from the Chairman, Notice of Annual General Meeting and Form
of Proxy have been issued to shareholders for the upcoming Annual General
Meeting for year ended 31 December 2022.

The Annual General Meeting will be held on 31 August 2023 at 8am in The Alex
Hotel Dublin, 41-47 Fenian Street, Dublin 2, D02 H678.

Copies of the Annual Report, Chairman's Letter, Notice AGM, Form of Proxy and
Annual Report are available online at https://healthbeacon.com/2023-agm/
(https://healthbeacon.com/2023-agm/) .

 

For further information, contact:

HealthBeacon plc

Unit 20

Naas Road Business Park

Muirfield Drive

Naas Road

Dublin 12

D12 WD85

 

T: +353 1 4508480

E: company.secretary@healthbeacon.com
(mailto:company.secretary@healthbeacon.com)

 

Goodbody (Euronext Listing Sponsor and Broker):

David
Kearney
+353 (1) 667 0420

Stephen Kane

 

About HealthBeacon:

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that

develops smart tools for managing medications for patients in the home.

 

The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics.

 

Peer reviewed evidence supports a 19% improvement in therapy persistence by
patients and up to 26% improvement in adherence to therapy, which improves
clinical outcomes and significantly improves efficiency in health systems.

 

The Company has expanded its offering to growth management with the launch of
its

integrated Smart Scale and oral adherence with the launch of HB Wave which
integrates

with its existing technology.

 

The Company operates across Europe, North America and the United Kingdom and
employs more than 70 people and has obtained more than 30 design and utility
patents.

The Company's mission is to become the world's leading digital therapeutics
platform for patients managing medications in the home.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEUPUUARUPWPGW